Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (May 2025)
19 slides from Neuroone Medical Technologies's investor presentation, May 13, 2025
Slide 1: Corporate Presentation
Corporate Presentation April 2025 NASDAQ: NMTC
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be
Slide 3: NeuroOne is a medical technology company transforming diagnosis and treatment of neurological disorders
3 NeuroOne is a medical technology company that is transforming the diagnosis and treatment of neurological disorders FDA - Cleared 3 FDA 510(k) cleared products for use in the brain, with the only FDA cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications
Slide 4: NeuroOne's next-generation electrode platform is highly disruptive and differentiated
4 Thin Film & Flexibility • Highly flexible design provides new options for surgical placement and potentially smaller borings/incisions • Lower inflammation compared to bulkier electrodes • Enables pairing of diagnostic and therapeutic procedures using the same sEEG • First 510(k) cleared device us
Slide 5: Mayo Clinic Partnership
5 Mayo Clinic Partnership • Mayo Clinic began testing technology in pre - clinical models and clinical research in 2015 • Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board • First commercial human use of Evo ® Cortical Electrodes performed at Mayo Clinic in
Slide 6: Zimmer Biomet Partnership
6 Zimmer Biomet Partnership Recently expanded partnership to include distribution rights for NeuroOne’s OneRF ® Ablation System • $3 million licensing fee • Distribution rights in US and select OUS countries • Expected to boost NeuroOne revenue growth and profitability • Zimmer is a worldwide leader
Slide 7: Our electrode platform addresses multi-billion $ and growing market needs
7 Brain Ablation Parkinson’s Epilepsy (Diagnostic Only) Spinal Cord Stimulation (Back Pain) Our electrode platform addresses multi - billion $ and growing market needs¹ $100M $500M+ $1B+ $3B $100M $5B+ $10B+ $1B+ Drug Delivery $0 $10B+ Actual Market Potential Market Size 1. Company data on file NASD
Slide 8: Technology Platform
8 Technology Platform NASDAQ: NMTC
Slide 9: Product Portfolio
9 Product Portfolio Application Status Use Case Product Diagnostic Currently marketed by Zimmer Biomet Recording brain activity Placed on surface of brain Evo® Cortical Electrodes Diagnostic Currently marketed by Zimmer Biomet Recording brain activity Placed Deeper Into the Brain Evo® sEEG Electrode
Slide 10: Thin-Film Evo sEEG & Cortical Electrodes
10 Summary • Increased signal clarity /reduced noise design • Cortical device thinner & lighter than competitive devices • sEEG - Better tactile feedback during brain tissue insertion • Both product lines are distributed by Zimmer Biomet Thin - Film Evo® sEEG & Cortical Electrodes Applications • Epi
Slide 11: OneRF Ablation System for Brain
11 OneRF ® Ablation System for Brain FDA 510(k) Clearance Summary • One procedure for diagnostic and therapeutic expected to save time, money and to improve patient outcomes • Temperature - guided ablation provides additional safety measure • Designed to reduce number of procedures and hospitalizati
Slide 12: OneRF Ablation System for Facial Pain (Trigeminal Neuralgia)
12 OneRF ® Ablation System for Facial Pain (Trigeminal Neuralgia - TN) FDA 510(k) Submitted Summary • Legacy TN RF ablation has proven clinical efficacy with established reimbursement • OneRF introduces the first multi - contact probe for TN ablation • This enables stimulation and ablation in target
Slide 13: Spinal Cord Percutaneous Paddle Lead
13 Spinal Cord Percutaneous Paddle Lead Summary • Percutaneously placed paddle electrodes for spinal cord stimulation • Able to stimulate broadly and precisely target tissue • Successfully completed initial testing for durability and stimulation for 5 - year use for recording and stimulation • Advis
Slide 14: sEEG-Based Drug Delivery System
14 sEEG - Based Drug Delivery System Designed to leverage our sEEG platform enabling drug delivery + brain activity recording Pre - Drug Delivery Record Brain Activity with sEEG Electrode(s) Drug Delivery Via Cannula Inserted Through sEEG Electrode(s) Post - Drug Delivery Record Brain Activity with
Slide 15: Our Management Team
15 Our Management Team Dave Rosa President & Chief Executive Officer Ron McClurg Chief Financial Officer Steve Mertens Chief Technology Officer Mark Christianson Co - Founder, Business Development Director, Medical Sales Liaison Hijaz Haris Vice - President of Marketing Camilo Diaz Botia Director of
Slide 16: Financial Overview
16 Financial Overview • Debt free balance sheet • Decreasing burn rate in FY2025 • FY2025 Guidance: • FY 2025 product revenue of $8.0 - $10.0M (132% - 190% increase vs. FY2024) • FY2025 product gross margin of 47% - 51% • New potential partnerships focused on pain management and drug delivery Highli
Slide 17: Upcoming Potential Catalysts
17 Upcoming Potential Catalysts • Zimmer Biomet OneRF ® Ablation System full launch • OneRF ® Trigeminal Nerve Ablation System FDA submission completed in April 2025 o Potential revenue in calendar 2025 for facial pain ablation system • Electrode revenue expected to more than double in FY2025 • Non
Slide 18: Key Takeaways
18 Key Takeaways Our platform technology of thin film electrode products improve outcomes for patients suffering from neurological disorders The only company with a single device that can perform multiple diagnostic & therapeutic functions such as recording, ablation and stimulation using the same e
Slide 19: Thank you
Thank you Dave Rosa Chief Executive Officer NASDAQ: NMTC ir@nmtc1.com
NeuroOne Medical Technologies — Investor Presentation (May 2025) on 6ix